ArticleFrontiers in public health2023

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.

Xueyan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.